RefleXion Medical
SCINTIX biology-guided radiotherapy is now FDA cleared.
SCINTIX biology-guided radiotherapy is now FDA cleared.
RefleXion Medical is a pioneering company that has gained $105.00M in Venture Round investment on 15 November 2023. The company, founded in 2009 and headquartered in the United States, operates in the Biotechnology and Health Care industries. RefleXion Medical's breakthrough technology, SCINTIX® therapy, has recently received FDA clearance and represents a significant advancement in the field of biology-guided radiotherapy. This innovative therapy detects and responds to signals emitted from cancer, using them to deliver immediate treatment for tumors in the lung or bone arising from primary or metastatic disease.
The recent Venture Round investment was led by a consortium of prominent investors, including Johnson & Johnson Innovation, Venrock, The Rise Fund, T. Rowe Price, Ally Bridge Group, Banque Pictet, Catalio Capital Management, Squarepoint Capital, Pfizer Venture Investments, and Hillenbrand Capital Partners, LLC.
This substantial investment underscores the confidence of industry leaders in RefleXion Medical's pioneering approach and the potential impact of SCINTIX® therapy on the treatment of cancer. The company's FDA clearance further solidifies its position as a frontrunner in the development of innovative and effective cancer treatment solutions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $105.00M | 10 |
|
15 Nov 2023 |
| Debt Financing | $125.00M | - | 06 Jul 2022 | |
| Series E | $80.00M | 10 |
|
10 Mar 2022 |
| Series D | $40.00M | 1 |
|
02 Mar 2021 |
| Series D | $100.00M | 8 |
|
17 Apr 2020 |
No recent news or press coverage available for RefleXion Medical.
We care about your data, and we'd love to use cookies make your experience better.
